221 related articles for article (PubMed ID: 27540956)
1. Detrimental effects of melanocortin-1 receptor (MC1R) variants on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors.
Guida M; Strippoli S; Ferretta A; Bartolomeo N; Porcelli L; Maida I; Azzariti A; Tommasi S; Grieco C; Guida S; Albano A; Lorusso V; Guida G
Pigment Cell Melanoma Res; 2016 Nov; 29(6):679-687. PubMed ID: 27540956
[TBL] [Abstract][Full Text] [Related]
2. Enhancing the Efficacy of Melanocortin 1 Receptor-Targeted Radiotherapy by Pharmacologically Upregulating the Receptor in Metastatic Melanoma.
Li M; Liu D; Lee D; Kapoor S; Gibson-Corley KN; Quinn TP; Sagastume EA; Mott SL; Walsh SA; Acevedo MR; Johnson FL; Schultz MK
Mol Pharm; 2019 Sep; 16(9):3904-3915. PubMed ID: 31318566
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data.
Czirbesz K; Gorka E; Balatoni T; Pánczél G; Melegh K; Kovács P; Gézsi A; Liszkay G
Pathol Oncol Res; 2019 Jan; 25(1):45-50. PubMed ID: 28963614
[TBL] [Abstract][Full Text] [Related]
4. Germline MC1R variants and BRAF mutant melanoma.
Hacker E; Hayward NK
J Invest Dermatol; 2008 Oct; 128(10):2354-6. PubMed ID: 18787543
[TBL] [Abstract][Full Text] [Related]
5. Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression.
Scholtens A; Geukes Foppen MH; Blank CU; van Thienen JV; van Tinteren H; Haanen JB
Eur J Cancer; 2015 Mar; 51(5):642-52. PubMed ID: 25690538
[TBL] [Abstract][Full Text] [Related]
6. MC1R variants increase risk of melanomas harboring BRAF mutations.
Fargnoli MC; Pike K; Pfeiffer RM; Tsang S; Rozenblum E; Munroe DJ; Golubeva Y; Calista D; Seidenari S; Massi D; Carli P; Bauer J; Elder DE; Bastian BC; Peris K; Landi MT
J Invest Dermatol; 2008 Oct; 128(10):2485-90. PubMed ID: 18368129
[TBL] [Abstract][Full Text] [Related]
7. Germline variation of the melanocortin-1 receptor does not explain shared risk for melanoma and thyroid cancer.
Bauer J; Weng J; Kebebew E; Soares P; Trovisco V; Bastian BC
Exp Dermatol; 2009 Jun; 18(6):548-52. PubMed ID: 19493000
[TBL] [Abstract][Full Text] [Related]
8. MC1R germline variants confer risk for BRAF-mutant melanoma.
Landi MT; Bauer J; Pfeiffer RM; Elder DE; Hulley B; Minghetti P; Calista D; Kanetsky PA; Pinkel D; Bastian BC
Science; 2006 Jul; 313(5786):521-2. PubMed ID: 16809487
[TBL] [Abstract][Full Text] [Related]
9. BRAF-V600 mutational status affects recurrence patterns of melanoma brain metastasis.
Maxwell R; Garzon-Muvdi T; Lipson EJ; Sharfman WH; Bettegowda C; Redmond KJ; Kleinberg LR; Ye X; Lim M
Int J Cancer; 2017 Jun; 140(12):2716-2727. PubMed ID: 27342756
[TBL] [Abstract][Full Text] [Related]
10. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
11. Association between the germline MC1R variants and somatic BRAF/NRAS mutations in melanoma tumors.
Scherer D; Rachakonda PS; Angelini S; Mehnert F; Sucker A; Egberts F; Hauschild A; Hemminki K; Schadendorf D; Kumar R
J Invest Dermatol; 2010 Dec; 130(12):2844-8. PubMed ID: 20720566
[No Abstract] [Full Text] [Related]
12. Three novel human sporadic melanoma cell lines: signaling pathways controlled by MC1R, BRAF and β-catenins.
Zanna P; Maida I; Grieco C; Guida S; Turpin Sevilla MC; De Summa S; Tommasi S; Vena GA; Filotico R; Guida G
J Biol Regul Homeost Agents; 2013; 27(1):131-41. PubMed ID: 23489693
[TBL] [Abstract][Full Text] [Related]
13. Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma.
Aya F; Fernandez-Martinez A; Gaba L; Victoria I; Tosca M; Pineda E; Gascon P; Prat A; Arance A
Clin Transl Oncol; 2017 Jan; 19(1):119-124. PubMed ID: 27147251
[TBL] [Abstract][Full Text] [Related]
14. Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma.
Kramkimel N; Thomas-Schoemann A; Sakji L; Golmard J; Noe G; Regnier-Rosencher E; Chapuis N; Maubec E; Vidal M; Avril M; Goldwasser F; Mortier L; Dupin N; Blanchet B
Target Oncol; 2016 Feb; 11(1):59-69. PubMed ID: 26208946
[TBL] [Abstract][Full Text] [Related]
15. Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma.
Mesbah Ardakani N; Leslie C; Grieu-Iacopetta F; Lam WS; Budgeon C; Millward M; Amanuel B
Pigment Cell Melanoma Res; 2017 Mar; 30(2):233-242. PubMed ID: 28002643
[TBL] [Abstract][Full Text] [Related]
16. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
Dummer R; Goldinger SM; Turtschi CP; Eggmann NB; Michielin O; Mitchell L; Veronese L; Hilfiker PR; Felderer L; Rinderknecht JD
Eur J Cancer; 2014 Feb; 50(3):611-21. PubMed ID: 24295639
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy with BRAF inhibitor therapy for melanoma: progress and possibilities.
Zahnreich S; Mayer A; Loquai C; Grabbe S; Schmidberger H
Future Oncol; 2016 Jan; 12(1):95-106. PubMed ID: 26616061
[TBL] [Abstract][Full Text] [Related]
18. Dermoscopic features of cutaneous melanoma are associated with clinical characteristics of patients and tumours and with MC1R genotype.
Fargnoli MC; Sera F; Suppa M; Piccolo D; Landi MT; Chiarugi A; Pellegrini C; Seidenari S; Peris K
J Eur Acad Dermatol Venereol; 2014 Dec; 28(12):1768-75. PubMed ID: 24588892
[TBL] [Abstract][Full Text] [Related]
19. Germline MC1R variants and frequency of somatic BRAF, NRAS, and TERT mutations in melanoma: Literature review and meta-analysis.
Zanna I; Caini S; Raimondi S; Saieva C; Masala G; Massi D; Cocorocchio E; Queirolo P; Stanganelli I; Gandini S
Mol Carcinog; 2021 Mar; 60(3):167-171. PubMed ID: 33444485
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
Menzies AM; Wilmott JS; Drummond M; Lo S; Lyle M; Chan MM; Thompson JF; Guminski A; Carlino MS; Scolyer RA; Kefford RF; Long GV
Cancer; 2015 Nov; 121(21):3826-35. PubMed ID: 26218930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
